Pilot study of anti-thymocyte globulin plus mycophenolate mofetil in recent-onset diffuse scleroderma.
OBJECTIVE: To assess the safety and efficacy of anti-thymocyte globulin (ATG) followed by mycophenolate mofetil (MMF) in the treatment of diffuse scleroderma. METHODS: A pilot study of 13 patients with recent- onset diffuse scleroderma was carried out. Patients received ATG for 5 days, followed by MMF for 12 months. We recorded adverse events, scleroderma skin score, hand contractures, EuroQol score, scleroderma functional assessment, pulmonary function studies, echocardiogram and plasma creatinine concentration. RESULTS: Mean skin score decreased during the study from 28 at baseline to 17 after 12 months of MMF (P<0.01). Hand contractures worsened during the study. Mean measurements of systemic disease remained stable. One patient died after a scleroderma renal crisis. Five patients developed serum sickness after ATG treatment, but this was controlled by corticosteroid therapy. MMF therapy was well tolerated. CONCLUSION: ATG and MMF appear safe in scleroderma. The improvement in skin score and the apparent stability of systemic disease during the study period suggest that controlled studies of these agents are justified
|Title:||Pilot study of anti-thymocyte globulin plus mycophenolate mofetil in recent-onset diffuse scleroderma|
|Additional information:||UI - 21113009 LA - eng RN - 0 (Anti-Inflammatory Agents, Non-Steroidal) RN - 0 (Antilymphocyte Serum) RN - 0 (Immunosuppressive Agents) RN - 128794-94-5 (mycophenolate mofetil) RN - 24280-93-1 (Mycophenolic Acid) PT - Clinical Trial PT - Controlled Clinical Trial PT - Journal Article DA - 20010222 IS - 1462-0324 SB - IM CY - England|
|Keywords:||ACID, ADVERSE, adverse events, AGENT, AGENTS, ANTITHYMOCYTE GLOBULIN, assessment, ATG, Concentration, Contracture, controlled study, corticosteroid, Creatinine, DEVELOPED, diffuse scleroderma, disease, EFFICACY, English, EVENTS, function, functional, GLOBULIN, graft, Hand, IMPROVEMENT, measurement, MEASUREMENTS, Methods, MMF, mycophenolate mofetil, MYCOPHENOLATE-MOFETIL, objective, OXFORD, PATHOGENESIS, Patient, patients, PERIOD, pilot, Pilot Studies, Pilot Study, plasma, PRESS, PROGRESSIVE SYSTEMIC-SCLEROSIS, pulmonary, PULMONARY FUNCTION, PULMONARY-FUNCTION, renal, Result, Rheumatology, SAFE, Safety, SCLERODERMA, SCLERODERMA RENAL CRISIS, SCLERODERMA SKIN, SERA, serum, Skin, ST, stability, SYSTEMIC, THERAPIES, therapy, treatment, adult, adverse effects, analogs & derivatives, Anti-Inflammatory Agents, Non-Steroidal, Antilymphocyte Serum, clinical, Clinical trial, CLINICAL-TRIAL, Controlled clinical trial, drug therapy, Drug Therapy, Combination, echocardiography, Female, IM, Immunosuppressive Agent, Immunosuppressive Agents, Kidney Function Tests, LA, Lymphocyte Count, Male, Middle Age, Mycophenolic Acid, ONSET, outcome assessment (health care), physiopathology, Pilot Projects, Respiratory Function Tests, Scleroderma, Systemic, therapeutic use, TRIAL|
|UCL classification:||UCL > School of Life and Medical Sciences
UCL > School of Life and Medical Sciences > Faculty of Medical Sciences
Archive Staff Only